WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H522528
CAS#: 902464-46-4
Description: UBP-310 is a potent and selective GLUK5 kainate receptor antagonist (IC50 = 130 nM). UBP-310also blocks recombinant homomeric GLUK7 receptors.
Hodoodo Cat#: H522528
Name: UBP-310
CAS#: 902464-46-4
Chemical Formula: C14H15N3O6S
Exact Mass: 353.07
Molecular Weight: 353.350
Elemental Analysis: C, 47.59; H, 4.28; N, 11.89; O, 27.17; S, 9.07
Synonym: UBP310, UBP 310, UBP-310
IUPAC/Chemical Name: (S)-3-((3-(2-amino-2-carboxyethyl)-5-methyl-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)methyl)thiophene-2-carboxylic acid
InChi Key: ZTAZUCRXCRXNSU-VIFPVBQESA-N
InChi Code: InChI=1S/C14H15N3O6S/c1-7-4-16(6-9(15)12(19)20)14(23)17(11(7)18)5-8-2-3-24-10(8)13(21)22/h2-4,9H,5-6,15H2,1H3,(H,19,20)(H,21,22)/t9-/m0/s1
SMILES Code: O=C1N(CC2=C(C(O)=O)SC=C2)C(C(C)=CN1C[C@H](N)C(O)=O)=O
Appearance: White solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 353.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Buldyrev I, Puthussery T, Taylor WR. Synaptic pathways that shape the excitatory drive in an OFF retinal ganglion cell. J Neurophysiol. 2012 Apr;107(7):1795-807. doi: 10.1152/jn.00924.2011. Epub 2011 Dec 28. PubMed PMID: 22205648; PubMed Central PMCID: PMC3331668.
2: Atlason PT, Scholefield CL, Eaves RJ, Mayo-Martin MB, Jane DE, Molnár E. Mapping the ligand binding sites of kainate receptors: molecular determinants of subunit-selective binding of the antagonist [3H]UBP310. Mol Pharmacol. 2010 Dec;78(6):1036-45. doi: 10.1124/mol.110.067934. Epub 2010 Sep 13. PubMed PMID: 20837679; PubMed Central PMCID: PMC2993462.
3: Perrais D, Pinheiro PS, Jane DE, Mulle C. Antagonism of recombinant and native GluK3-containing kainate receptors. Neuropharmacology. 2009 Jan;56(1):131-40. doi: 10.1016/j.neuropharm.2008.08.002. Epub 2008 Aug 12. PubMed PMID: 18761361.
4: Du M, Rambhadran A, Jayaraman V. Luminescence resonance energy transfer investigation of conformational changes in the ligand binding domain of a kainate receptor. J Biol Chem. 2008 Oct 3;283(40):27074-8. doi: 10.1074/jbc.M805040200. Epub 2008 Jul 24. PubMed PMID: 18658129; PubMed Central PMCID: PMC2556009.
5: Mayer ML, Ghosal A, Dolman NP, Jane DE. Crystal structures of the kainate receptor GluR5 ligand binding core dimer with novel GluR5-selective antagonists. J Neurosci. 2006 Mar 15;26(11):2852-61. PubMed PMID: 16540562.
